Julie Wang

发表

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

J. W. Kim, M. Ikeda, Li‐Tzong Chen, 2022, NEJM evidence.

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.

N. Rokutanda, T. Okusaka, V. Breder, 2024, The Lancet. Oncology.